Thor submits its BPR dossier for Union Authorisation of the C(M)IT/MIT Biocidal Product Family

In the first week of June Thor submitted a BPR1 dossier for Union Authorisation of the C(M)IT/MIT2 Biocidal Product Family including more than 20 ACTICIDE® products.

Following the publication of the Commission Implementing Regulation (EU) 2016/131 of 1 February 2016 approving C(M)IT/MIT as an existing active substance for use in biocidal products, Thor has submitted its dossier for the C(M)IT/MIT Biocidal Product Family. This submission was made approximately one month ahead of the deadline date of 1 July 2017. Thor has supported a Union Authorisation for the C(M)IT/MIT Biocidal Product Family including the product types 2, 4, 6, 11, 12 and 13, covering more than 25 applications.

The BPR concerns the placing on the market as well as the use of biocidal products. Under the BPR, (which replaced the BPD3 on 1 September 2013), all biocidal active substances contained in biocidal products are subject to an application-related evaluation which started with the establishment of the Review Programme in 2000 with a forecasted completion date in 2024. Following the approval of an individual active substance, all biocidal products containing this individual substance need to be authorised.

Thor has conducted studies and applied in use scenarios for each biocidal formulation and the summary of product characteristics (SPCs) was developed to ensure that the stringent risk assessments of the BPR are met for multiple applications, such as the preservation of paints and coatings, slimicide action in paper mills and microbial control in cooling and heating systems.

With the submission of the dossier, the product Authorisations of Thor customers were initiated either as a marketing company or for Same Biocidal Product Authorisation. Thor’s partners were able to rely on Thor’s expertise during the whole process and thus were able to save both time and money.

To learn more about the measures Thor takes to support customers with Product Authorisations under the BPR, please contact us by email: or talk to one of our sales representatives.

 1 BPR - Biocidal Products Regulation (EU) 528/2012 (BPR)

2 Reaction mass of 5-chloro-2-methyl-2H-isothiazol-3-one (EINECS 247-500-7) and 2-methyl-2H-isothiazol-3-one (EINECS 220-239-6) (3:1) (Mixture of C(M)IT/MIT)

3 BPD - Biocidal Products Directive (98/8/EC)


Thor busy at the ECS

It was a busy three days for Thor at this years European Coatings Show, the major biannual show for the paint and coatings industry which took place in Nuremberg 4 - 6 April.

Substantial interest was shown in ACTICIDE® C1 / SCT technology, an innovative MIT free system complying with potential restrictions on MIT in the future. In addition, numerous other MIT free products were discussed with existing and potential customers from around the globe.

Thor representatives from the Performance Chemicals division were also on hand to discuss new developments in flame retardants for coatings and other applications.


Thor China Opening

Thor has confirmed its commitment to the Asia Pacific market with the opening of its newly commissioned facility in Zhenjiang, China.

Phase 1 of the 50,000m2 site, at a total investment of USD 50m, is complete and fully operational marked by the official opening ceremony in April. The facility comprises 3,000m2 offices and laboratories, 5,000m2 warehousing and a production plant capable of an output in excess of 30,000 tonnes of Thor’s in-can and dry film ACTICIDE® biocides, extensive range of liquid and solid Microcare® quats and AFLAMMIT® flame retardant products.

Thor's Mark Jamieson, Regional Director, Asia Pacific confirmed "This new facility will ensure ready product availability, not only to the Chinese domestic market, but also to the whole region, in particular our expanding markets in Australia, Taiwan, Korea and Japan.

This major new development for the Group comes on top of the recent expansion of a similar multi-million dollar facility in Querétaro Mexico to supply the Americas which, along with its principal European facility in Speyer Germany and six further manufacturing sites worldwide, strengthens Thor’s position as a global supplier of speciality chemicals.